Bayer AG

General information
Bayer AG
Kaiser-Wilhelm-Allee 1
51373 Leverkusen, North Rhine-Westphalia
Germany

Contact person: Thomas Kornek, Vice President Investor Relations
Company main phone: +49 (214) 301
Website:  https://www.bayer.com/
Year founded:1863
Source of foundation:Independent foundation
No. of employees: Worldwide:  98189
Corporate description / mission:
Bayer is a global life science company specializing in healthcare and nutrition. The company operates through three segments: crop science, pharmaceuticals, and consumer health. The Crop Science segment engages in the development, production, and marketing of seeds, plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health, specialty therapeutics in the areas of oncology, hematology, and ophthalmology, as well as diagnostic imaging equipment and contrast agents. The consumer health segment offers nonprescription over-the-counter medicines, medical products, cosmetics, and other self-care solutions in the categories of dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cough and cold.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1988
Categorization
Sector:
  • Pharma (fully integrated)
Subsector:
  • Anti-infectives
  • Antibodies
  • Cell therapy
  • Gene therapy
  • Immunotherapy
  • Nucleic acid drugs
  • Peptides
  • Small molecule therapeutics
  • Stem cells
  • Other
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Consumers (mass market)
  • Hospitals
  • Physicians / doctors
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical:5
Phase I:23
Phase II:8
Phase III:12
On the market:3
Number of Medtech Products
In development:2
Description of products:
Darolutamide
Finerenone
Vericiguat, etc.
Financing details
Fiscal year (end of) 2023
Revenues:USD 51'543.23M
R&D expenses:USD 5'811.42M
Cash:USD 6'391.37M
Total liabilities:USD 90'001.84M
No. of shares:982'424'000
Market cap. / valuation:USD 27'520.91M
X